Skip to main content
Log in

Plasma and urinary digoxin in thyroid dysfunction

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The response to a single oral dose of 0.5 mg digoxin has been studied in eight patients, of whom four were hyperthyroid and four were hypothyroid, both before and after treatment for their thyroid dysfunction. The post-dose plasma digoxin levels were significantly lower in the hyperthyroid patients when they were thyrotoxic than when they became euthyroid. In only one hypothyroid patient was the post-dose plasma digoxin level significantly higher before treatment than it was after and in the others the digoxin values reached were either the same as, or lower than, before treatment. There was a significant correlation between the creatinine clearance and the urinary concentrations of digoxin and these both altered with change in thyroid status. Total urinary digoxin excretion did not change. Pharmacokinetic analysis suggested that digoxin was distributed in a way compatible with a two-compartment model and that the volume of the central compartment was high in thyrotoxic patients and low in hypothyroid patients. In both cases it reverted to a median value after treatment. It is recommended that plasma digoxin levels should be monitored in all patients with thyroid dysfunction who require therapeutic digoxin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Crookson, H.: The thyroid and the heart. Brit. Med. J.1959/I, 254

    Google Scholar 

  2. Frye, R.L., Braunwald, E.: Studies on digitalis III. The influence of triiodothyronine on digitalis requirements. circulation23, 376–382 (1961)

    Google Scholar 

  3. Conney, A.H., Garren, L.: Contrasting effects of thyroxine on zoxazolamine and hexobarbital metabolism. Biochem. Pharmacol.6, 257–262 (1968)

    Google Scholar 

  4. Kato, R., Takahashi, A.: Thyroid hormone and activities of drugmetabolising enzymes and electron transport systems of rat liver microsomes. Molec. Pharmacol.4, 109–120 (1968)

    Google Scholar 

  5. Crooks, J., Hedley, A.J., MacNee, C., Stevenson, L.H.: Changes in drug metabolising ability in thyroid disease. Brit. J. Pharmacol.49, 156P-157P (1973)

    Google Scholar 

  6. Eichelbaum, M., Bodem, G., Gugler, R., Schneider-deters, C., Dengler, H.J.: Influence of thyroid status on plasma half-life of antipyrine in man. N. Engl. J. Med.290, 1040–1042 (1974)

    Google Scholar 

  7. Doherty, J.E., Perkins, W.H.: Digoxin metabolism in hypo- and hyperthyroidism. Studies with tritiated digoxin in thyroid disease. Ann. Int. Med.64, 489–507 (1966)

    Google Scholar 

  8. Eickenbusch, W., Lahrtz, H., Seppelt, U., Van Zwieten, P.A.: Serum concentration and urinary excretion of3H-ouabain and3H-digitoxin in patients suffering from hyperthyroidism or hypothyroidism. Klin. Wschr.5, 270–275 (1970)

    Google Scholar 

  9. Croxson, M.S., Ibbertson, H.K.: Serum digoxin in patients with thyroid disease. Brit. Med. J.1975/3, 566–568

    Google Scholar 

  10. Gilfrich, H.J.: Untersuchungen zur Pharmakokinetik von Digoxin bei hyperthyreoten Patienten. Verh. der Dtsch. Ges. Inn. Med.82, 1726–1728 (1976)

    Google Scholar 

  11. Eichelbaum, M.: Drug Metabolism in Thyroid Disease. Clin. Pharmakokinetics1, 339–350 (1976)

    Google Scholar 

  12. Horn, D.B.: Unpublished data

  13. Greenwood, H., Snedden, W., Hayward, R.P., Landon, J.: The measurement of urinary digoxin and dihydrodigoxin by radioimmunoassay and by mass spectroscopy. Clin. Chim. Acta62 (2), 213–224 (1975)

    Google Scholar 

  14. Sedman A.J. and Wagner, J.G.: A decision-making Pharmacokinetic computer program. Publication Distribution Service, 615 East University Avenue, Ann Arbor, Michigan 48106, USA (1974)

  15. Metzler, C.M.: Nonlin. The Upjohn Company Technical Report 7292/69/7292/005. Kalamazoo, Michigan, USA (1969)

  16. Buccino, R.A., Spann, J.F. Jnr., Pool, P.E.: Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J. Clin. Invest.46, 1669–1682 (1967)

    Google Scholar 

  17. Peacock, W.F., Moran, N.C.: Influence of thyroid state on positive inotropic effect of ouabain on isolated rat ventriclestrips. Proc. Soc. Exp. Biol. Med.113, 526–530 (1963)

    Google Scholar 

  18. Morrow, D.H., Gaffney, T.E., Braunwald, E.: Studies on digitalis VII. Influence of hyper- and hypothyroidism on the myocardial response to ouabain. J. Pharmacol. Exp. Ther.140, 324–328 (1963)

    Google Scholar 

  19. Kalk, W.J., Lawrence, J.R., Ratcliffe, W.A., Sumner, D.J., Whiting, B.: Digoxin pharmacokinetics in hyperthyroidism. Brit. J. Clin. Pharmacol.3, 954P (1976)

  20. Aronson, J.K., Grahame-Smith, D.G.: Digoxin therapy: textbooks, theory and practice. Brit. J. Clin. Pharmacol.3, 639–648 (1976)

    Google Scholar 

  21. Bloom, P.M., Nelp, W.B.: Relationship of the excretion of tritiated digoxin to renal function. Amer. J. Med. Sci.251, 133–144 (1966)

    Google Scholar 

  22. Sumner, D.J., Russell, A.J., Whiting, B.: Digoxin pharmacokinetics: multicompartmental analysis and its clinical implications. Brit. J. Clin. Pharmacol.3, 221–229 (1976)

    Google Scholar 

  23. Bradley, S.E., Stephen, F., Coelho, J.B., Reville, P.: The thyroid and the kidney. Kidney Internat.6, 346–365 (1974)

    Google Scholar 

  24. Doherty, J.E., Ferrell, C.B., Towbin, E.J.: Localisation of the renal excretion of tritiated digoxin. Amer. J. Med. Sci.258, 181–189 (1968)

    Google Scholar 

  25. Steiness, E.: Renal tubular secretion of digoxin. Circulation50, 103–107 (1974)

    Google Scholar 

  26. Hartmann, C.R., Klaassen, C.D., Huffman, D.H.: The biliary excretion of digoxin and metabolites in hyperthyroid rats. Clin. Res.23, 220A (1975)

  27. Kemp, J.R., Greenblatt, D.J., Jusko, W.J., Smith, T.W., Koch-weser, J.: Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J. Pharmacokin. Biopharm.3, 181–192 (1975)

    Google Scholar 

  28. Hall, W.H., Doherty, J.E.: Tritiated digoxin XVI. Gastric absorption. Digest. Dis.16, 903–908 (1971)

    Google Scholar 

  29. Thomas, F.B., Caldwell, J.W., Greenberger, N.J.: Steatorrhea in thyrotoxicosis. Relation to hypermotility and excessive dietary fat. Ann. Intern. Med.78, 669–675 (1973)

    Google Scholar 

  30. Watters, K., Tomkin, G.H.: Serum digoxin in patients with thyroid disease. Brit. Med. J.1975/4, 102

    Google Scholar 

  31. Evered, D.C.: The binding of digoxin by the serum proteins. Europ. J. Pharmacol.18, 236–244 (1972)

    Google Scholar 

  32. Smith, T.W., Haber, E.: Digitalis (Third of four parts). Pharmacokinetics and bioavailability. N. Engl. J. Med.289, 1063–1072 (1973)

    Google Scholar 

  33. Lindsay, R., Parker, J.L.W.: Rat hepatic sodium plus postassium iondependent adenosine triphosphatase after treatment with digoxin and thyroxine. Clin. Sci. Mol. Med.50, 329–332 (1976)

    Google Scholar 

  34. Chamberlain, D.A., White, R.J., Howard, M.R., Smith, T.W.: Plasma digoxin concentrations in patients with atrial fibrillation. Brit. Med. J.1970/3, 429–432

    Google Scholar 

  35. Parker, J.L.W., Lawson, D.H.: Death from thyrotoxicosis. Lancet1973/II, 894–895

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shenfield, G.M., Thompson, J. & Horn, D.B. Plasma and urinary digoxin in thyroid dysfunction. Eur J Clin Pharmacol 12, 437–443 (1977). https://doi.org/10.1007/BF00561063

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00561063

Key words

Navigation